

1 **Humoral and Cellular Immunogenicity and Safety of 3 Doses of CoronaVac and**
2 **BNT162b2 in Young Children and Adolescents with Kidney Diseases**

3
4 Daniel Leung,^{1,*} Eugene Yu-hin Chan,^{2,*} Xiaofeng Mu,^{1,*} Jaime S Rosa Duque,^{1,*} Samuel
5 MS Cheng,^{3,*} Fanny Tsz-wai Ho,² Pak-chiu Tong,² Wai-ming Lai,² Matthew HL Lee,⁴ Stella
6 Chim,⁴ Issan YS Tam,¹ Leo CH Tsang,³ Kelvin KH Kwan,³ Yuet Chung,¹ Howard HW Wong,¹
7 Amos MT Lee,¹ Wing Yan Li,¹ Summer TK Sze,¹ Jennifer HY Lam,¹ Derek HL Lee,¹ Sau
8 Man Chan,¹ Wenwei Tu,^{1,†} Malik Peiris,^{3,5,†} Alison Lap-tak Ma,^{2,†} Yu Lung Lau,^{1,†}

9 ¹ Department of Pediatrics and Adolescent Medicine, The University of Hong Kong, Hong
10 Kong, China

11 ² Pediatric Nephrology Centre, Department of Pediatrics and Adolescent Medicine, Hong
12 Kong Children's Hospital, Hong Kong, China

13 ³ School of Public Health, The University of Hong Kong, Hong Kong, China

14 ⁴ Department of Pediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong,
15 China

16 ⁵ Centre for Immunology & Infection C2i, Hong Kong, China

17

18 *, denotes co-first authors who contributed equally

19 †, denotes co-corresponding authors who contributed equally

20

21 **Running Title: CoronaVac and BNT162b2 in pediatric kidney patients**

22 **Corresponding authors:**

23 Wenwei Tu, MBBS, PhD

24 Email: wwtu@hku.hk

25 Address: 7/F, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong.

26

27 Malik Peiris, MBBS, DPhil

28 Email: malik@hku.hk

29 Address: Centre for Immunology & Infection, 11/F, Building 17W, Hong Kong
30 Science Park, Shatin, Hong Kong.

31

32 Alison Lap-tak Ma, MBBS, FRCPCH(UK)

33 Email: malta@ha.org.hk

34 Address: 9/F, Tower B, Hong Kong Children's Hospital, Kowloon Bay,
35 Hong Kong.

36

37 Yu Lung Lau, MBChB, MD(Hons)

38 Email: lauylung@hku.hk

39 Address: 1/F, New Clinical Building, Queen Mary Hospital, Pokfulam, Hong Kong.

40

41 **Key words:** BNT162b2, CoronaVac, COVID-19, kidney diseases, vaccine

42 **Length:** 2912 words (excluding Methods)

43 **Tables and Figures:** 2 and 5

44

45 **Funding:** HKSAR Government COVID19F02, COVID19F10, and COVID19F12.

46 **SIGNIFICANCE STATEMENT**

47 Little is known about the effectiveness of COVID-19 vaccines in children and adolescents
48 with kidney diseases. This paper describes the antibody and T cell responses of 3 doses of
49 CoronaVac or BNT162b2, the top 2 COVID-19 vaccines distributed worldwide, by an
50 accelerated regimen in patients with kidney diseases aged 1-18 years. Antibody and T cell
51 responses were significantly elicited by either vaccine. Neutralization was reduced against
52 Omicron while T cell response was preserved, which likely confer protection against severe
53 COVID-19. Rate of severe adverse reactions was low in the study. Results confirm that
54 accelerated 3-dose primary series with CoronaVac and BNT162b2 is safe and immunogenic
55 in young children and adolescents with kidney diseases.

56

57 **ABSTRACT**

58 Background: Patients with kidney diseases are at risk of severe complications from COVID-
59 19, yet little is known about the effectiveness of COVID-19 vaccines in children and
60 adolescents with kidney diseases.

61 Methods: We investigated the immunogenicity and safety of an accelerated, 3-dose primary
62 series of COVID-19 vaccines among 64 pediatric chronic kidney disease patients (mean age
63 12.2; 32 male) with or without immunosuppression, dialysis, or kidney transplant.

64 CoronaVac was given to those aged <5 years, 0.1ml BNT162b2 to those aged 5-11 years,
65 and 0.3ml BNT162b2 to those aged 11-18 years.

66 Results: Antibody responses including S-RBD IgG (90.9-100% seropositive) and surrogate
67 virus neutralization (geometric mean sVNT% level, 78.6-94.0%) were significantly elicited by
68 3 doses of any vaccine. T cell responses were also elicited. Weaker neutralization
69 responses were observed among kidney transplant recipients and non-dialysis children
70 receiving rituximab for glomerular diseases. Neutralization was reduced against Omicron
71 BA.1 compared to wild-type (post-dose 3 sVNT% level; 84% vs 27.2%; $p < 0.0001$). However,
72 T cell response against Omicron BA.1 was preserved, which likely confer protection against

73 severe COVID-19. Hybrid immunity was observed after vaccination in infected patients, as
74 evidenced by higher Omicron BA.1 neutralization response among infected patients
75 receiving 2 doses than those uninfected. Generally mild or moderate adverse reactions
76 following vaccines were reported.

77 Conclusions: Our findings support that an accelerated 3-dose primary series with CoronaVac
78 and BNT162b2 is safe and immunogenic in young children and adolescents with kidney
79 diseases.

80

81 **TRIAL REGISTRATION**

82 Clinicaltrials.gov NCT04800133

83 **INTRODUCTION**

84 Patients with chronic kidney disease and kidney failure are at risk of severe disease and
85 mortality in the COVID-19 pandemic.¹ Impaired immune function in children and adolescents
86 with severe kidney diseases predisposes them to infections,² and vaccination offers
87 protection to this vulnerable population. BNT162b2 is an mRNA vaccine with 90-100%
88 efficacy against symptomatic COVID-19 caused by pre-Omicron variants in healthy children
89 and adolescents aged 5-15 years.^{3,4} CoronaVac is a whole-virus inactivated vaccine with
90 robust immunogenicity and real-world effectiveness demonstrated in children aged 3-17
91 years.⁵⁻⁸ In many places, including Hong Kong, immunocompromised children and
92 adolescents are recommended to receive a 3-dose mRNA or inactivated vaccine primary
93 series, due to their clinical vulnerability and suboptimal immunogenicity.⁹

94

95 We have previously shown that the antibody responses elicited by 2 doses of BNT162b2
96 were diminished in adolescents with kidney diseases.¹⁰ However, data pertaining to the
97 immunogenicity and safety of COVID-19 vaccines among the pediatric population remain
98 extremely scarce.^{11,12} Data concerning the humoral and cellular immunogenicity to 3-dose
99 primary series of COVID-19 vaccines among young children with kidney diseases, as well as
100 immunogenicity against the Omicron variant, are lacking.

101

102 We initiated a 3-year non-randomized study (NCT04800133) to investigate the use of
103 COVID-19 vaccines in children and adolescents in Hong Kong. In the present interim
104 analysis, we recruited younger children and adolescents aged 0-18 years with advanced
105 chronic kidney disease (CKD, stage 3 or above), and those on immunosuppressive therapy,
106 on chronic dialysis and post-kidney transplant as they are clinically vulnerable. We evaluated
107 the immunogenicity and safety in participants who had initiated or completed a 3-dose
108 primary series of either CoronaVac (age <5 years), or BNT162b2 (0.1ml dose for 5-11 years,
109 and 0.3ml dose for 11-18 years).

110 **METHODS**

111 **Study Design**

112 COVID-19 Vaccination in Adolescents and Children (COVAC; NCT04800133) is a non-
113 randomized study investigating the safety and immunogenicity of BNT162b2 and
114 CoronaVac, in healthy children and adolescents or those with pediatric illnesses as
115 previously described.^{10,13,14} The study was approved by the University of Hong Kong/Hong
116 Kong West Cluster Hospital Authority Institutional Review Board (UW21-157).

117

118 **Participants**

119 The current analysis included children and adolescents, aged 0-18 years, with advanced
120 chronic kidney disease (CKD, stage 3 or above), and those on immunosuppressive therapy,
121 on chronic dialysis and post-kidney transplant. All patients received at least two doses of
122 COVID-19 vaccine at the time of analysis. Participants with no known history of kidney
123 diseases were excluded from this analysis.

124

125 **Procedures**

126 Potential participants were recruited by pediatricians from the Pediatric Nephrology Centre,
127 Hong Kong Children's Hospital and the Department of Pediatrics and Adolescent Medicine,
128 Queen Mary Hospital in Hong Kong. The Pediatric Nephrology Centre in Hong Kong
129 Children's Hospital is the territory-wide, designated pediatric referral center for complicated
130 kidney diseases and chronic kidney replacement therapy, including dialysis and transplant.
131 Clinicians obtained informed consent from participants aged 18 years. Informed assent was
132 obtained from participants aged below 18, and consent was obtained from their parents or
133 legally acceptable representatives. Participants were either unvaccinated, or partially
134 vaccinated at the time of enrollment. Demographic information was reported by participants,
135 and clinical information were extracted from their health records. In our study, 0.5ml
136 CoronaVac was offered to participants aged below 5 years, 0.1ml BNT162b2 was offered to

137 participants aged 5-11 years as the original pediatric formulation was not available in Hong
138 Kong, and 0.3ml BNT162b2 was offered to participants aged 11-18 years. Participants who
139 received an alternative COVID-19 vaccine as the first or second dose prior to joining the
140 study would complete the remaining doses with the vaccine brand indicated for their age in
141 our study protocol. Additional consent and assent were obtained for dosage switching to
142 0.3ml for participants who became 12 years old after initiating the primary series. CoronaVac
143 and BNT162b2 were administered via the intramuscular route to the deltoid or the
144 anterolateral thigh, or, in some for 0.3ml BNT162b2, by an intradermal inoculator
145 (MicronJet600, NanoPass Technologies, Nes Ziona, Israel) to the deltoid. Doses 2 and 3
146 were given at least 14 and 28 days after the preceding dose. Vaccination was deferred in
147 patients with SARS-CoV-2 infection and was resumed or initiated 28 days later. All
148 participants were observed by a nurse or pediatrician after each dose for at least 15 minutes
149 after vaccination on site. Blood-taking and safety data collection were performed pre-dose 1,
150 pre-dose 2, post-dose 2 (14-42 days after dose 2), pre-dose 3 (blood-taking was only
151 performed for participants who received dose 3 more than 56 days after their post-dose 2
152 visit), and post-dose 3 (14-42 days after dose 3).

153

154 **Immunogenicity**

155 Humoral

156 Primary outcomes on humoral immunogenicity included wild-type (WT, i.e. ancestral) Spike
157 receptor-binding domain (S-RBD) IgG ELISA and WT surrogate virus neutralization test
158 (sVNT). While the S-RBD IgG is a binding antibody assay, the sVNT is a functional antibody
159 assay which reflects blocking of S-RBD and human ACE2 receptor by vaccinee sera and
160 correlates with the gold-standard plaque reduction neutralization test.¹⁵ Secondary outcome
161 was Omicron BA.1 sVNT. In-house WT S-RBD IgG enzyme-linked immunosorbent assay
162 (ELISA) were carried out as previously published.^{13,16} sVNT was conducted as per
163 manufacturer's instructions (GenScript Inc, Piscataway, USA).¹⁶

164

165 Cellular

166 Primary outcomes on cellular immunogenicity included antiviral cytokine-expressing (IFN- γ ⁺
167 or IL-2⁺) helper (CD4⁺) or cytotoxic (CD8⁺) T cell responses against SARS-CoV-2 S (and N
168 and M) proteins. They were examined by intracellular cytokine staining on flow cytometry
169 after stimulation with SARS-CoV-2 15-mer peptide pool(s) (Miltenyi Biotec, Bergisch
170 Gladbach, Germany) as described previously.^{13,14,17} SARS-CoV-2 S peptide pool was used
171 for BNT162b2 while S, N and M peptide pools were used for CoronaVac as it is an
172 inactivated whole-virus vaccine. Frequencies of T cell responses against S, N and M peptide
173 pools were summated for CoronaVac. Secondary outcomes on cellular immunogenicity
174 included T cell responses to stimulation by BA.1 S (and N and M) mutation pools, which
175 consists of 15-mer peptides spanning the regions with BA.1-associated mutations only, were
176 examined with WT reference pools consisting of WT sequences in the same regions as the
177 comparator (Miltenyi Biotec, Bergisch Gladbach, Germany for S mutation pools and
178 ChinaPeptides, Shanghai, China for N and M mutation pools).^{14,17}

179

180 Analysis

181 Outcome data on immunogenicity were transformed by taking natural logarithm of the values
182 and compared longitudinally using paired t test. Negative values, i.e., those below the limit of
183 detection (LOD), limit of quantification (LOQ) or cut-off, were imputed as half the limit or cut-
184 off and included in the analyses. Certain WT T cell and Omicron-specific antibody and T cell
185 responses could only be performed in participants with sufficient blood sample volume.

186 Additional details are available in the Supplemental Methods.

187

188 **Safety and reactogenicity**

189 Participants reported pre-specified adverse reactions (ARs) in an online or paper-based
190 diary for 7 days after vaccination. Unsolicited adverse events (AEs) were captured for up to

191 28 days after each dose. Severe AEs, including life-threatening complications, unanticipated
192 or prolonged hospitalizations, disabilities, deaths and birth defects of their offspring, or
193 breakthrough COVID-19, would be monitored for 3 years after vaccination. We also
194 monitored graft rejection among kidney transplant recipients and disease flare among those
195 with glomerular disease following vaccination. Adverse events reported were reviewed by
196 investigators, who determined any possibility of causal relationship with the study vaccine.

197 **RESULTS**

198 **Participant composition**

199 A total of 64 children and adolescents with kidney diseases (mean age 12.2, interquartile
200 range 9.4-16.2, and 32 male) received at least one dose of COVID-19 vaccine, including 5
201 aged 1-5 years for CoronaVac, 25 aged 5-11 years for 0.1ml BNT162b2, and 34 aged 11-18
202 years for 0.3ml BNT162b2 (Table 1). Thirteen patients were on dialysis, 15 patients
203 underwent kidney transplant, and 31 patients were on immunosuppressives alone at the
204 time of dose 1. All participants had Asian heritage. The details of these patients, grouped
205 according to their treatment, are summarized in Table S1. Five patients aged 14-18 years
206 elected to receive dose 3 BNT162b2 intradermally.

207

208 **Primary immunogenicity analysis of longitudinal antibody responses by vaccine type**

209 We studied antibody responses as they have been shown to correlate with vaccine efficacy
210 against symptomatic COVID-19.¹⁸ We tracked antibody responses against WT SARS-CoV-
211 2, including S-RBD IgG for binding antibody and sVNT for neutralization, longitudinally from
212 the pre-vaccine baseline to post-dose 3 by vaccine type in Fig. 1A and 1B respectively. S-
213 RBD IgG and sVNT responses rose significantly for all 3 vaccine types/ages after 3 doses
214 when compared to pre-dose 1 on paired t test after natural logarithmic transformation.

215 For patients who received the 3-dose primary series of CoronaVac (aged <5 years), all
216 children tested positive for S-RBD IgG (above LOD of 0.5, considered 'seropositive') and
217 had a high geometric mean sVNT% level of 94.0%. For patients who received the 3-dose
218 primary series of BNT162b2, 73.9% and 93.8% of the participants aged 5-11 years (who
219 received 0.1ml BNT162b2) were seropositive after doses 2 and 3, with geometric mean
220 sVNT% levels of 51.7% and 78.6%. These figures were similar to 11-18 years age group
221 (who received 0.3ml BNT162b2) where 81.8% and 90.9% of the participants were
222 seropositive, with geometric mean sVNT% levels of 60.5% and 80.0% after doses 2 and 3
223 respectively. Compared against 2 doses only, an additional third dose of 0.1ml and 0.3ml

224 BNT162b2 both elicited significant increases in S-RBD IgG and sVNT. Four patients who
225 received 2 intramuscular and 1 intradermal dose of 0.3ml BNT162b2 had a high geometric
226 mean sVNT% level of 95.7% post-dose 3. S-RBD IgG and sVNT responses were also
227 presented by kidney replacement therapy status in Table 2.

228

229 **Primary immunogenicity analysis of longitudinal T cell responses by vaccine type**

230 We also studied T cell responses as they protect against progression to severe COVID-19.¹⁹

231 For patients who received CoronaVac (< 5 years), IFN- γ^+ antiviral CD4⁺ helper and CD8⁺
232 cytotoxic T cell responses against SARS-CoV-2 S, N and M proteins were examined
233 longitudinally in Fig 2. In addition, CD4⁺ and CD8⁺ T cells expressing another antiviral
234 cytokine, IL-2, were also studied (Fig. S1A-D). In patients who received CoronaVac (<5
235 years), we detected a significant increase of SNM-specific IFN- γ^+ CD4⁺ T cell response (Fig.
236 2B). Other T cell responses also trended to increase, albeit insignificantly. Yet, all 5 patients
237 who received 3 doses of CoronaVac were positive for either S-specific or SNM-specific IFN-
238 γ^+ CD4⁺ and CD8⁺ T cells.

239

240 For patients who received BNT162b2, T cell response against S protein only was examined.
241 After 3 doses of BNT162b2, we detected significant increases in all S-specific IFN- γ^+ and IL-
242 2⁺ CD4⁺ and CD8⁺ T cell responses (Fig. 2A, 2C), except for S-specific IL-2⁺ CD8⁺ T cell
243 response in those aged 5-11 years who received 0.1ml BNT162b2 (Fig. S1). Four patients
244 who received an intradermal dose 3 of 0.3ml BNT162b2 appeared to have a similar level of
245 T cell responses as those who received intramuscular dose 3.

246

247 **Antibody and T cell responses against Omicron BA.1**

248 As a secondary outcome, Omicron BA.1 neutralization was evaluated by sVNT. When
249 compared with paired WT sVNT, we found a significant lower sVNT% level against Omicron
250 BA.1 following dose 2 (64.1% vs 18.5%, $P < 0.0001$) and dose 3 (84.0% vs 27.2%, $P < 0.0001$)

251 (Fig. 3A), indicating that BA.1 markedly evades neutralization compared to WT in kidney
252 patients. However, we observed a significant increase in geometric mean BA.1 sVNT% level
253 with dose 3 (post-dose 2 vs post-dose 3, 18.5% vs 27.2%, $P=0.006$).

254

255 We then assayed IFN- γ^+ CD4 $^+$ and CD8 $^+$ T cells responses against Omicron BA.1 mutations
256 in S, N and M after 2 doses of vaccine. Notably, T cell responses against Omicron BA.1 and
257 WT S protein were comparable after 2 doses of any vaccine (Fig. 3B). Similarly, in patients
258 aged <5 years who received CoronaVac, N-specific and M-specific T cell responses were
259 comparable between Omicron BA.1 and WT (Fig. 3C-D), suggesting T cell responses were
260 not diminished by mutations in Omicron BA.1.

261

262 **Correlation of immunogenicity with vaccine type and treatment modality**

263 We explored correlation of immunogenicity with age or type of vaccine, and treatment as a
264 secondary analysis. We focused on post-dose 2 WT sVNT because antibody assays are
265 more sensitive than T cell assays and correlates with plaque neutralization better than S-
266 RBD IgG. No correlation with immunogenicity was found for age or type of vaccine.

267 However, compared to non-dialysis patients who were not on immunosuppressives, a
268 significantly lower sVNT level was detected for both kidney transplant recipients (geometric
269 mean ratio of sVNT% 0.38, 95% CI 0.16-0.90; $P=0.03$) and patients who received rituximab
270 within 1 year preceding vaccination (geometric mean ratio of sVNT% 0.32, 95% CI 0.13-
271 0.77; $P=0.02$) (Fig. 4). In contrast, patients on chronic dialysis demonstrated a similar
272 antibody response to non-dialysis patients not on immunosuppression ($P=0.27$).

273

274 **Breakthrough COVID-19 cases and hybrid immunity**

275 From January 2022, Hong Kong was hit by the first major wave of COVID-19 resulting from
276 Omicron BA.2 variant. Eleven patients (17% of all participants) reported COVID-19 during
277 that time, including 7 (11%) before and 4 (6%) after initiating COVID-19 vaccination. All

278 patients reported mild COVID-19 without the need of hospitalization. No mortality was
279 reported. Two patients had a longer clinical course with rapid antigen test positivity for 14
280 and 17 days. They were both unvaccinated and treated with immunosuppressive therapy for
281 underlying glomerular disease. Two patients had breakthrough COVID-19 after completing 3
282 doses, and both had a high WT sVNT% level above 90% (93.7% and 90.6%) tested shortly
283 before breakthrough infection. Both patients were managed conservatively without
284 complications.

285

286 We also investigated the effect of hybrid immunity, which refers to the synergized immune
287 response from both vaccination and infection, in patients who were infected prior to
288 vaccination (Fig. S2A-C). Before vaccination, only two patients out of 7 seroconverted to
289 infection alone, and one of them had a positive yet weak neutralizing response (Fig. S2A).
290 After receiving 2 doses of vaccine, infected patients showed significantly boosted S-RBD
291 IgG and WT sVNT responses (Fig. S2A). When compared to uninfected patients who
292 received 2 doses of vaccine, infected and vaccinated patients also had a higher Omicron
293 BA.1 sVNT (Fig. S2B). For T cell responses among infected patients, S-specific IFN- γ^+ CD4⁺
294 T cells were significantly increased after 2 doses compared to pre-dose 1, and S-specific
295 IFN- γ^+ CD8⁺ T cells showed an upward trend as well (Fig. S2C).

296

297 **Safety and reactogenicity**

298 We tracked ARs for 7 days and AEs for 28 days after each dose. COVID-19 vaccination
299 appeared tolerable in our patients. Patients receiving either vaccine brand mainly reported
300 mild and moderate ARs (Fig. 5). Two and 5 AEs were reported within 28 days after 0.1ml
301 and 0.3ml BNT162b2, including 2 reports after dose 1 and 5 reports after dose 2. They
302 included chest discomfort (n=1), palpitations (n=2), tachycardia (n=1), epistaxis (n=1),
303 insomnia (n=1), and tinnitus (n=1). All AEs were grade 1 except for the report of tinnitus,
304 which was grade 2. None of the kidney transplant recipients developed graft rejection during

305 the follow-up period. Of the 31 non-dialysis patients with glomerular disease, 2 patients
306 (6.4%) developed disease relapse closely following vaccination, 1 of whom required
307 hospitalization. Two more patients experienced relapse, but their relapses could be
308 attributable to acute COVID-19 and to B cell reconstitution 12 months after rituximab,
309 respectively. Four patients reported a non-fatal resolved severe AE after study vaccine
310 administration, including one for nephrotic syndrome relapse, one with suspected
311 myopericarditis, one with prolonged post-vaccine fever and one with catheter-associated
312 infection. All patients with an SAE recovered without complications. More details regarding
313 adverse events are available in Supplemental Information.

314 **DISCUSSION**

315 In this study, we demonstrated that an accelerated, 3-dose COVID-19 vaccine schedule with
316 CoronaVac (<5 years) and BNT162b2 at age-appropriate dose (5-18 years) elicited
317 favorable antibody and T cell responses. However, weaker antibody responses were found
318 in patients who received kidney transplant or rituximab. Although Omicron BA.1 mutations
319 led to partial neutralization escape, dose 3 significantly enhanced neutralization capacity.
320 Importantly, T cell responses against Omicron BA.1 were comparable to that with WT,
321 suggesting effective protection from severe COVID-19 by vaccination.

322

323 We showed a significant induction of S-RBD IgG and WT sVNT antibody responses
324 regardless of vaccine type and age. Antibody response is the first line of defense against
325 infection and has been shown to correlate with efficacy against COVID-19,¹⁸ Therefore, our
326 results suggest that 3 doses of COVID-19 vaccines could offer protection against COVID-19
327 in children and adolescents with kidney diseases. In contrast to healthy adolescents who
328 have a 100% seropositivity after a single dose of BNT162b2,¹³ 4 out of 47 (9%) patients
329 failed to develop antibody responses after 3 doses of vaccine. Similarly, studies on adult
330 patients who are on dialysis or post-kidney transplant also demonstrated weak antibody
331 responses, related to the immunosuppressed state in kidney failure and immunosuppressive
332 therapy.^{20,21} In our study, kidney transplant recipients and patients receiving rituximab for
333 glomerular disease were identified to have lower antibody response. This is likely to be due
334 to intense humoral immunosuppression by triple therapy post-transplant or by rituximab.
335 Rituximab has emerged as an important therapeutic option in several pediatric immune-
336 mediated glomerular diseases, such as idiopathic nephrotic syndrome and ANCA-associated
337 vasculitis glomerulonephritis.^{2,22,23} Our data showed that rituximab exposure up to 1 year
338 prior to vaccination resulted in poor immunogenicity. Furthermore, patients with glomerular
339 disease are at risk of relapse and often require multiple courses of rituximab to maintain
340 disease remission.²² Therefore, the timing of vaccination and rituximab should be

341 individualized, balancing the risk of infection and disease relapse. Fortunately, our current
342 findings did not suggest an overtly increased risk of graft rejection and disease relapse
343 following vaccination, indicating the safety of COVID-19 vaccination in children and
344 adolescents with kidney diseases.

345

346 The SARS-CoV-2 Omicron variant has caused repeated surges in COVID-19 cases and
347 hospitalizations across the globe, with more than 30 mutations in S protein which cause
348 extensive neutralization escape and reduce the effectiveness of COVID-19 vaccines.²⁴⁻²⁶
349 According to our data, when compared with WT sVNT, we found that a significantly lower
350 sVNT% level against Omicron BA.1 following doses 2 and 3, signifying partial neutralization
351 escape. However, neutralization capacity was significantly enhanced by dose 3 from 18.5%
352 to 27.2%. We postulate that further booster doses may further optimize the immunogenicity
353 and protection in children and adolescents with kidney diseases, as a fourth dose has been
354 found to seroconvert adult kidney transplant recipients who were seronegative after 3
355 doses.²⁷ Interestingly, our data suggested that T cell responses remained robust against
356 Omicron even with a WT vaccine, in line with observations in healthy adolescents.^{14,17} T cell
357 responses against SARS-CoV-2, including towards non-S proteins,²⁸ may protect against
358 progression to severe COVID-19 after a breakthrough infection,¹⁹ even against variants of
359 concerns with major neutralization escape.

360

361 We only observed mild infections after vaccination in our cohort. It was known that either a
362 post-vaccine breakthrough infection or vaccination following infection improves the
363 magnitude and diversity of immune response, leading to hybrid immunity that could be
364 longer-lasting and cross-reactive towards novel variants.²⁹ Our data showed that only 28%
365 patients seroconverted to infection alone. Yet, Omicron BA.1 sVNT after 2 doses among
366 infected patients was significantly higher than that of uninfected vaccinated patients. This
367 further supports the need of vaccination in pediatric kidney patients even after SARS-CoV-2

368 infection, as this will generate hybrid immunity, and enhance protection against future
369 variants. Although few of our vaccinated participants experienced a breakthrough infection,
370 allow us to investigate their immune responses, those vaccinated and experienced a
371 breakthrough infection should likewise complete all recommended doses for maximal
372 protection. Nonetheless, we advocate for continued personal hygiene measures to minimize
373 the chance of a severe breakthrough COVID-19 in children and adolescents with kidney
374 diseases.

375

376 In this study, we vaccinated young children under age 5 with full-dose CoronaVac, an
377 inactivated COVID-19 vaccine, and children aged 5-11 years with 0.1ml BNT162b2. Real-
378 world effectiveness data in Hong Kong collected during the BA.2.2 wave showed
379 comparable effectiveness against severe and fatal COVID-19 after 3 doses of either vaccine
380 brand in adults,²⁶ and against infection after 2 doses of either vaccine brand in children and
381 adolescents.⁸ The investigators preferred BNT162b2 for children and adolescents with
382 kidney diseases as there were more effectiveness data on mRNA COVID-19 vaccines in
383 immunocompromised patients.^{30,31} Yet, the pediatric formulation of BNT162b2 was not made
384 available to Hong Kong, and we adopted dosage reduction, injecting 0.1ml for an equivalent
385 potency of 10mcg, with reference to United Kingdom Joint Committee on Vaccination and
386 Immunization advice for children in a clinically risk group in December 2021.³² In children
387 below 5 years, as safety and immunogenicity data were published for CoronaVac and not for
388 BNT162b2 at the time of the Omicron BA.2.2 wave in Hong Kong,⁵ we offered CoronaVac to
389 young children and infants with kidney diseases urgently. Our findings suggest both 0.1ml
390 BNT162b2 and CoronaVac were safe and immunogenic and support their use in children
391 with kidney diseases.

392

393 Furthermore, due to the rapid Omicron BA.2 wave in Hong Kong during study period, we
394 administered the vaccines using an accelerated regimen, with 14-day interval between

395 doses 1 and 2, and 28-day interval between doses 2 and 3. While longer prime-boost
396 intervals are associated with better immunogenicity in general,³³ seronegativity after just 1 or
397 2 doses was common in our study, and it was important for our vulnerable patients to
398 immediately attain a higher level of protection within a short timeframe before catching
399 Omicron. We showed that the accelerated regimen was still able to elicit antibody and T cell
400 responses significantly in children and adolescents with kidney diseases and speculate that
401 their immune responses will also be boosted by breakthrough infections and booster doses.

402

403 Moreover, while our study conducted antibody and T cell testing under a research protocol,
404 clinicians might be tempted to base their decisions of vaccination or boosting on SARS-CoV-
405 2 antibody testing. However, the 2 participants who received all 3 doses of vaccines prior to
406 infection both showed high WT sVNT antibody response (>90%) prior to acute COVID-19.
407 This suggests antibody testing in an individual patient cannot be used to predict
408 susceptibility to infection nor to guide booster decision.

409

410 Our study had strengths and limitations. We tracked antibody and T cell responses
411 longitudinally in a relatively large cohort of vaccinated children and adolescents with different
412 kidney diseases and treatments aged 1-18 years and provided the first Omicron-specific
413 neutralization and T cell responses in this patient population. We could not assess clinical
414 effectiveness, nor compare immunogenicity of vaccine brands in the same age groups.
415 Sample number available for a particular test and timepoint was limited by the blood volume
416 collected and completion of study visit by the participant. As we used 0.1ml dose of the adult
417 formulation for BNT162b2, reactogenicity and immunogenicity could potentially differ from
418 that of the actual pediatric formulation.

419

420 In conclusion, our findings support that an accelerated, 3-dose primary series of mRNA or
421 inactivated COVID-19 vaccines is safe and immunogenic for children and adolescents with

422 kidney diseases, especially among kidney transplant recipients and patients receiving
423 rituximab therapy. Although neutralization response against Omicron was reduced, T cell
424 response was preserved and may offer protection to children and adolescents with kidney
425 diseases from severe COVID-19. Further studies are needed to shed light on the
426 immunogenicity of a fourth dose and hybrid immunity in immunocompromised children in the
427 future.

428 **STATEMENT OF CONTRIBUTION**

429 Y.L. Lau conceptualized the study. Y.L. Lau, M. Peiris, W. Tu, D. Leung, J.S. Rosa Duque,
430 and X. Mu designed the study. Y.L. Lau led the acquisition of funding. Y.L. Lau, W. Tu, and
431 M. Peiris supervised the project. S.M. Chan, D. Leung, X. Mu, S.M.S. Cheng, I.Y.S. Tam,
432 and J.H.Y. Lam led the study administrative procedures. A.L.T. Ma, Y.L. Lau, J.S. Rosa
433 Duque, E.Y.H. Chan, S. Chim, F.T.W. Ho, P.C. Tong, W.M. Lai, and M.H.L. Lee provided
434 study-related clinical assessments and follow-up. D. Leung, S.M. Chan, S.T.K. Sze, J.H.Y.
435 Lam, J.S. Rosa Duque, and Y.L. Lau collected clinical safety data. S.M.S. Cheng, L.C.H.
436 Tsang, K.K.H. Kwan, and M. Peiris developed and performed S-RBD IgG and sVNT. X. Mu,
437 Y. Chung, H.H.W. Wong, A.M.T. Lee, W.Y. Li, and W. Tu developed and performed the T
438 cell assays. D. Leung, D.H.L. Lee, and J.H.Y. Lam curated, analyzed, and visualized the
439 data. D. Leung, X. Mu, S.M.S. Cheng, J.S. Rosa Duque, D.H.L. Lee, J.H.Y. Lam, and S.M.
440 Chan validated the data. D. Leung and E.Y.H. Chan drafted the manuscript and were
441 supervised by A.L.T. Ma, J.S. Rosa Duque, and Y.L. Lau, with input from X. Mu, and S.M.S.
442 Cheng. All authors reviewed and approved the final manuscript.

443

444 **ACKNOWLEDGEMENTS**

445 We thank the staff at Community Vaccination Centers at Ap Lei Chau Sports Centre,
446 Gleneagles Hospital Hong Kong, and Sun Yat-Sen Memorial Park Sports Centre. The
447 investigators are grateful to all clinical research team members and laboratory staff of
448 Department of Pediatrics and Adolescent Medicine of the University of Hong Kong, for their
449 research support. We are most thankful to the study participants, as well as clinicians and
450 laboratory staff who have provided clinical care and testing to the patients.

451

452 **DISCLOSURES**

453 The authors declare no conflicts of interest.

454

455 **FUNDING**

456 This study was supported by the research grants COVID19F02, COVID19F10, and
457 COVID19F12 from the Hong Kong SAR Government, which was not involved in the study
458 design, performance, interpretation, or publication of this project.

459

460 **DATA SHARING**

461 All requests to share the pseudonymized data underlying the conclusions of this paper from
462 researchers will be facilitated by the authors, subject to ethics approval. Enquiries should be
463 addressed to lauylung@hku.hk.

464

465 **SUPPLEMENTAL MATERIALS**

466 Supplemental Methods

467 Supplemental Information: Safety and Reactogenicity

468 REFERENCES

- 469 1. Jdiaa, S.S., Mansour, R., El Alayli, A., Gautam, A., Thomas, P., and Mustafa, R.A. (2022).
470 COVID-19 and chronic kidney disease: an updated overview of reviews. *J Nephrol* 35, 69-85.
471 10.1007/s40620-021-01206-8.
- 472 2. Chan, E.Y.H., Yap, D.Y.H., Wong, W.H.S., Ho, T.W., Tong, P.C., Lai, W.M., Chan, T.M., and
473 Ma, A.L.T. (2022). Demographics and long-term outcomes of children with end-stage kidney disease:
474 A 20-year territory-wide study. *Nephrology (Carlton)* 27, 171-180. 10.1111/nep.14007.
- 475 3. Frenck, R.W., Jr., Klein, N.P., Kitchin, N., Gurtman, A., Absalon, J., Lockhart, S., Perez, J.L.,
476 Walter, E.B., Senders, S., Bailey, R., et al. (2021). Safety, Immunogenicity, and Efficacy of the
477 BNT162b2 Covid-19 Vaccine in Adolescents. *N Engl J Med* 385, 239-250. 10.1056/NEJMoa2107456.
- 478 4. Walter, E.B., Talaat, K.R., Sabharwal, C., Gurtman, A., Lockhart, S., Paulsen, G.C., Barnett,
479 E.D., Muñoz, F.M., Maldonado, Y., Pahud, B.A., et al. (2022). Evaluation of the BNT162b2 Covid-19
480 Vaccine in Children 5 to 11 Years of Age. *N Engl J Med* 386, 35-46. 10.1056/NEJMoa2116298.
- 481 5. Han, B., Song, Y., Li, C., Yang, W., Ma, Q., Jiang, Z., Li, M., Lian, X., Jiao, W., Wang, L., et
482 al. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine
483 (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2
484 clinical trial. *The Lancet Infectious Diseases* 21, 1645-1653. 10.1016/s1473-3099(21)00319-4.
- 485 6. Jara, A., Undurraga, E.A., Zubizarreta, J.R., Gonzalez, C., Acevedo, J., Pizarro, A., Vergara,
486 V., Soto-Marchant, M., Gilabert, R., Flores, J.C., et al. (2022). Effectiveness of CoronaVac in children
487 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile. *Nat Med*. 10.1038/s41591-022-
488 01874-4.
- 489 7. Florentino, P., Alves, F., Cerqueira-Silva, T., Oliveira, V.d.A., Júnior, J.B., Jantsch, A., Penna,
490 G., Boaventura, V., Werneck, G., Pearce, N., et al. (2022). Vaccine effectiveness of CoronaVac
491 against symptomatic and severe COVID-19 among children in Brazil during the Omicron period. *Res*
492 *Sq*. 10.21203/rs.3.rs-1604882/v1.
- 493 8. Leung, D., Duque, J.R., Yip, K.M., So, H.K., Wong, W., and Lau, Y.L. (2022). Effectiveness of
494 BNT162b2 and CoronaVac in children and adolescents against SARS-CoV-2 infection during
495 Omicron BA.2 wave in Hong Kong. *Res Sq*. 10.21203/rs.3.rs-1856540/v1.
- 496 9. Centre for Health Protection, Hong Kong. Recommendation for additional dose(s) of COVID-
497 19 vaccination. (2022).
- 498 10. Ma, A.L.-T., Leung, D., Chan, E.Y.-H., Chim, S., Cheng, S., Ho, F.T.-W., Lai, W.-M., Tong, P.-
499 C., Lee, M.H.-L., Wong, W.H.-S., et al. (2022). Antibody responses to 2 doses of mRNA COVID-19
500 vaccine in pediatric patients with kidney diseases. *Kidney International* 101, 1069-1072.
- 501 11. Crane, C., Phebus, E., and Ingulli, E. (2022). Antibody response to 2- and 3-dose SARS-CoV-
502 2 mRNA vaccination in pediatric and adolescent kidney transplant recipients. *Pediatr Nephrol*.
503 10.1007/s00467-022-05661-8.
- 504 12. Crane, C., Phebus, E., and Ingulli, E. (2022). Immunologic response of mRNA SARS-CoV-2
505 vaccination in adolescent kidney transplant recipients. *Pediatr Nephrol* 37, 449-453. 10.1007/s00467-
506 021-05256-9.
- 507 13. Rosa Duque, J., Wang, X., Leung, D., Cheng, S., Cohen, C., Mu, X., Hachim, A., Zhang, Y.,
508 Chan, S.-M., Chaothai, S., et al. (2022). Immunogenicity and reactogenicity of SARS-CoV-2 vaccines
509 BNT162b2 and CoronaVac in healthy adolescents. *Nat Commun* 13, 3700.
510 <https://doi.org/10.1038/s41467-022-31485-z>.

- 511 14. Leung, D., Cohen, C.A., Mu, X., Rosa Duque, J., Cheng, S.M., Wang, X., Wang, M., Zhang,
512 W., Zhang, Y., Tam, I.Y., et al. (2022). Immunogenicity Against Wild-Type and Omicron SARS-CoV-2
513 After a Third Dose of Inactivated COVID-19 Vaccine in Healthy Adolescents. SSRN: Cell Press Sneak
514 Peek. <https://ssrn.com/abstract=4115862>.
- 515 15. Perera, R., Ko, R., Tsang, O.T.Y., Hui, D.S.C., Kwan, M.Y.M., Brackman, C.J., To, E.M.W.,
516 Yen, H.L., Leung, K., Cheng, S.M.S., et al. (2021). Evaluation of a SARS-CoV-2 Surrogate Virus
517 Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera. J Clin
518 Microbiol 59. 10.1128/JCM.02504-20.
- 519 16. Perera, R.A., Mok, C.K., Tsang, O.T., Lv, H., Ko, R.L., Wu, N.C., Yuan, M., Leung, W.S.,
520 Chan, J.M., Chik, T.S., et al. (2020). Serological assays for severe acute respiratory syndrome
521 coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill 25. 10.2807/1560-
522 7917.ES.2020.25.16.2000421.
- 523 17. Mu, X., Cohen, C.A., Leung, D., Duque, J.S.R., Cheng, S.M.S., Chung, Y., Wong, H.H.W.,
524 Lee, A.M.T., Li, W.Y., Tam, I., et al. (2022). Antibody and T cell responses against wild-type and
525 Omicron SARS-CoV-2 after the third dose of BNT162b2 in healthy adolescents. Res Sq.
526 10.21203/rs.3.rs-1961385/v1.
- 527 18. Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., Subbarao,
528 K., Kent, S.J., Triccas, J.A., and Davenport, M.P. (2021). Neutralizing antibody levels are highly
529 predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 27, 1205-1211.
530 10.1038/s41591-021-01377-8.
- 531 19. Openshaw, P.J.M. (2022). Using correlates to accelerate vaccinology. Science 375, 22-23.
532 10.1126/science.abn0007.
- 533 20. Schrezenmeier, E., Rincon-Arevalo, H., Stefanski, A.L., Potekhin, A., Straub-Hohenbleicher,
534 H., Choi, M., Bachmann, F., Pross, V., Hammett, C., Schrezenmeier, H., et al. (2021). B and T Cell
535 Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. J Am Soc
536 Nephrol. 10.1681/ASN.2021070966.
- 537 21. Praet, J.V., Reynders, M., Bacquer, D.D., Viaene, L., Schoutteten, M.K., Caluwe, R., Doubel,
538 P., Heylen, L., Bel, A.V.D., Vlem, B.V., et al. (2021). Predictors and Dynamics of the Humoral and
539 Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter
540 Observational Study. Journal of American Society of Nephrology 32, 3208-3220.
- 541 22. Chan, E.Y.-h., Yu, E.L.M., Angeletti, A., Arslan, Z., Basu, B., Boyer, O., Chan, C.-Y., Colucci,
542 M., Dorval, G., Dossier, C., et al. (2022). Long-Term Efficacy and Safety of Repeated Rituximab to
543 Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study. Journal of
544 the American Society of Nephrology 33, 1193-1207. 10.1681/asn.2021111472.
- 545 23. Marlais, M., Wlodkowski, T., Printza, N., Kronsteiner, D., Krisam, R., Sauer, L., Aksenova, M.,
546 Ashoor, I., Awan, A., Bacchetta, J., et al. (2022). Clinical Factors and Adverse Kidney Outcomes in
547 Children With Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. Am J Kidney Dis.
548 10.1053/j.ajkd.2022.05.013.
- 549 24. Cele, S., Jackson, L., Khoury, D.S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J.E.,
550 Cromer, D., Scheepers, C., Amoako, D.G., et al. (2022). Omicron extensively but incompletely
551 escapes Pfizer BNT162b2 neutralization. Nature 602, 654-656. 10.1038/s41586-021-04387-1.
- 552 25. Cheng, S.M.S., Mok, C.K.P., Leung, Y.W.Y., Ng, S.S., Chan, K.C.K., Ko, F.W., Chen, C., Yiu,
553 K., Lam, B.H.S., Lau, E.H.Y., et al. (2022). Neutralizing antibodies against the SARS-CoV-2 Omicron
554 variant following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med.
555 10.1038/s41591-022-01704-7.

- 556 26. McMenamin, M.E., Nealon, J., Lin, Y., Wong, J.Y., Cheung, J.K., Lau, E.H.Y., Wu, P., Leung,
557 G.M., and Cowling, B.J. (2022). Vaccine effectiveness of one, two, and three doses of BNT162b2 and
558 CoronaVac against COVID-19 in Hong Kong: a population-based observational study. *The Lancet*
559 *Infectious Diseases*. 10.1016/s1473-3099(22)00345-0.
- 560 27. Masset, C., Benotmane, I., Dantal, J., Garandeau, C., Gauthier-Vargas, G., Cantarovich, D.,
561 Meurette, A., Giral, M., Caillard, S., and Blancho, G. (2022). A fourth SARS-CoV-2 mRNA vaccine in
562 strictly seronegative kidney transplant recipients. *Kidney Int* 101, 825-826. 10.1016/j.kint.2022.01.017.
- 563 28. Peng, Y., Felce, S.L., Dong, D., Penkava, F., Mentzer, A.J., Yao, X., Liu, G., Yin, Z., Chen,
564 J.L., Lu, Y., et al. (2022). An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls
565 viral replication and is associated with less severe COVID-19 disease. *Nat Immunol* 23, 50-61.
566 10.1038/s41590-021-01084-z.
- 567 29. Cao, Y., Song, W., Wang, L., Liu, P., Yue, C., Jian, F., Yu, Y., Yisimayi, A., Wang, P., Wang,
568 Y., et al. (2022). Characterizations of enhanced infectivity and antibody evasion of Omicron BA.2.75.
569 *bioRxiv*, 2022.2007.2018.500332. 10.1101/2022.07.18.500332.
- 570 30. Oliver, M.J., Thomas, D., Balamchi, S., Ip, J., Naylor, K., Dixon, S.N., McArthur, E., Kwong,
571 J., Perl, J., Atiqzaman, M., et al. (2022). Vaccine Effectiveness Against SARS-CoV-2 Infection and
572 Severe Outcomes in the Maintenance Dialysis Population in Ontario, Canada. *J Am Soc Nephrol* 33,
573 839-849. 10.1681/ASN.2021091262.
- 574 31. Sibbel, S., McKeon, K., Luo, J., Wendt, K., Walker, A.G., Kelley, T., Lazar, R., Zywno, M.L.,
575 Connaire, J.J., Tentori, F., et al. (2022). Real-World Effectiveness and Immunogenicity of BNT162b2
576 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis. *J Am Soc Nephrol* 33, 49-57.
577 10.1681/ASN.2021060778.
- 578 32. JCVI statement on COVID-19 vaccination of children and young people: 22 December 2021.
579 [https://www.gov.uk/government/publications/jcvi-update-on-advice-for-covid-19-vaccination-of-](https://www.gov.uk/government/publications/jcvi-update-on-advice-for-covid-19-vaccination-of-children-and-young-people/jcvi-statement-on-covid-19-vaccination-of-children-and-young-people-22-december-2021)
580 [children-and-young-people/jcvi-statement-on-covid-19-vaccination-of-children-and-young-people-22-](https://www.gov.uk/government/publications/jcvi-update-on-advice-for-covid-19-vaccination-of-children-and-young-people/jcvi-statement-on-covid-19-vaccination-of-children-and-young-people-22-december-2021)
581 [december-2021](https://www.gov.uk/government/publications/jcvi-update-on-advice-for-covid-19-vaccination-of-children-and-young-people/jcvi-statement-on-covid-19-vaccination-of-children-and-young-people-22-december-2021).
- 582 33. Voysey, M., Costa Clemens, S.A., Madhi, S.A., Weckx, L.Y., Folegatti, P.M., Aley, P.K.,
583 Angus, B., Baillie, V.L., Barnabas, S.L., Bhorat, Q.E., et al. (2021). Single-dose administration and the
584 influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19
585 (AZD1222) vaccine: a pooled analysis of four randomised trials. *The Lancet* 397, 881-891.
586 10.1016/s0140-6736(21)00432-3.
587

1 **TABLE 1. Participant profile by vaccine type and age.** eGFR (estimated glomerular filtration
 2 rate) is estimated by modified Schwartz equation for participants below age 18 years and CKD-
 3 EPI formula for those above. KRT, kidney replacement therapy


	All patients	CoronaVac, <5 years	BNT162b2, 5-11 years, 0.1ml	BNT162b2, 11-18 years, 0.3ml
Number of participants <i>N</i>	64	5	25	34
Age mean (interquartile range)	12.2 (9.4 – 16.2)	3.3 (3.1-3.6)	9.1 (8.6-12.1)	15.7 (10.5-16.4)
Sex male n:female n	32:32	2:3	12:13	18:16
Number of participants completing 2 doses <i>n</i> (%)	64 (100%)	5 (100%)	25 (100%)	34 (100%)
Number of participants completing 3 doses <i>n</i> (%)	51 (80%)	5 (100%)	17 (68%)	29 (85%)
Primary kidney diagnosis <i>n</i> (%)				
CAKUT	10 (16%)	1 (20%)	4 (16%)	5 (15%)
Glomerular diseases	36 (56%)	3 (60%)	15 (60%)	18 (53%)
Hereditary	11 (17%)	1 (20%)	4 (16%)	6 (18%)
Miscellaneous	7 (11%)	0 (0%)	2 (8%)	5 (15%)
Treatment modality <i>n</i> (%)				
No KRT	36 (56%)	4 (80%)	16 (64%)	16 (47%)
On immunosuppression	31 (48%)	2 (40%)	14 (56%)	15 (44%)
KRT				
Kidney transplant	15 (23%)	0 (0%)	7 (28%)	8 (24%)
Dialysis	13 (20%)	1 (20%)	2 (8%)	10 (29%)
Vintage of KRT mean (range)	5.7 (1-18)	2 (2)	6.2 (2-10)	5.6 (1-18)
Concurrent immunosuppression within 3 months <i>n</i> (%)				
Mycophenolate mofetil	32 (50%)	1 (20%)	13 (52%)	18 (53%)
Prednisolone	38 (59%)	1 (20%)	15 (60%)	22 (65%)
Azathioprine	3 (5%)	0 (0%)	0 (0%)	3 (9%)
Cyclosporine A	2 (3%)	0 (0%)	1 (4%)	1 (3%)
Tacrolimus	29 (45%)	1 (20%)	13 (52%)	15 (44%)
Everolimus	4 (6%)	0 (0%)	3 (12%)	1 (3%)
Hydroxychloroquine	6 (9%)	0 (0%)	1 (4%)	5 (15%)
Rituximab	3 (5%)	1 (20%)	0 (0%)	2 (6%)
None	14 (22%)	3 (60%)	3 (12%)	8 (24%)
Immunosuppression within 1 year <i>n</i> (%)				
Rituximab	9 (14%)	1 (20%)	2 (8%)	6 (18%)
Kidney function and proteinuria mean (range)				
eGFR (ml/min/1.73m ²)	88.1 (20-234)	97.0 (20-234)	91.2 (20-184)	84.0 (24-145)
Urine protein/creatinine ratio (mg/mmol)	33.9 (1.6-140)	22.7 (14-32)	29.8 (1.6 -140)	40.2 (6-108)
Blood count and comorbidities				
Hypertension <i>n</i> (%)	38 (59%)	4 (80%)	12 (48%)	22 (65%)
Absolute lymphocyte count (x10 ⁶ /ml) mean (range)	2.5 (0.48-6.47)	4.5 (3.27-6.47)	2.9 (1-5.59)	2.0 (0.48-5.18)

4 **TABLE 2. Antibody responses including S-RBD IgG and surrogate virus neutralization**
 5 **test (sVNT) against wild-type SARS-CoV-2 by treatment status.** Number of seropositive
 6 patients by S-RBD IgG were given by n/N (%) and geometric mean sVNT with 95% confidence
 7 intervals (CIs) were shown. KRT, kidney replacement therapy

	No KRT			On KRT	
	No IS	Any IS	Rituximab	Dialysis	Transplant
S-RBD IgG seropositivity (%)					
Pre-dose 2	4/4 (100%)	14/29 (48.3%)	2/9 (22.2%)	8/12 (66.7%)	3/12 (25.0%)
Post-dose 2	5/5 (100%)	23/30 (76.7%)	5/9 (55.6%)	11/11 (100.0%)	10/15 (66.7%)
Post-dose 3	4/4 (100%)	19/20 (95.0%)	3/4 (75.0%)	8/8 (100.0%)	9/11 (81.8%)
Geometric mean sVNT% level (95% CI)					
Pre-dose 2	67.0% (47.3-100.6%)	28.6% (21.7-37.6%)	21.3% (12.5-36.4%)	39.4% (24.6-63.0%)	21.4% (14.1-32.4%)
Post-dose 2	96.5% (95.0-97.9%)	57.2% (42.8-76.4%)	30.7% (15.6-60.6%)	91.5% (85.5%-97.9%)	37.0% (22.6- 60.6%)
Post-dose 3	97.4% (96.1-98.8%)	86.5% (71.1-105.2%)	60.8% (13.8-267.9%)	95.9% (93.9-98.0%)	59.4% (35.9- 98.2%)


8

9 **FIG. 1. Antibody responses against wild-type SARS-CoV-2 including (A) S-RBD IgG for**
 10 **binding and (B) surrogate virus neutralization test (sVNT) for neutralization.** Matched pre-
 11 dose 1 or post-dose 2 tests were compared with post-dose 3 by paired t test after natural
 12 logarithmic transformation, and p values are denoted by asterisks (*, $P < 0.05$; **, $P < 0.01$; ****,
 13 $P < 0.0001$; ns, not significant). Geometric means (GM) are shown with center lines and stated
 14 above each column. Limits of detection and quantification (LOD and LOQ) were drawn as grey
 15 lines. Data points of patients who received intradermal 0.3ml BNT162b2 as dose 3 were
 16 depicted as rhombi, and those of infected patients were drawn to be hollow beginning from after
 17 the infection.




18

19 **FIG. 2. IFN- γ T cell responses against wild-type SARS-CoV-2 proteins.** T cell responses
 20 against S protein were tested for all participants while responses against S, N and M proteins
 21 were only tested for CoronaVac. Matched pre-dose 1 and post-dose 3 tests were compared by
 22 paired t test after natural logarithmic transformation, and p values are denoted by asterisks (*,
 23 P<0.05; **, P<0.01; ***, P<0.001; ns, not significant). Geometric means (GM) are shown with
 24 center lines and stated above each column. Cut-offs were drawn as grey lines. Data points of
 25 patients who received intradermal 0.3ml BNT162b2 as dose 3 were depicted as rhombi, and
 26 those of infected patients were drawn to be hollow beginning from after the infection.




27

28 **FIG. 3. Antibody and T cell response against Omicron BA.1.** Matched WT and BA.1 tests
 29 were compared by paired t test after natural logarithmic transformation, and the p values are
 30 denoted by asterisks (**, $P < 0.01$; ****, $P < 0.0001$; ns, not significant). Geometric means (GM)
 31 are shown with center lines and stated above each column. Limit of quantification (LOQ) and
 32 cut-offs were drawn as grey lines. Data points were colored orange, navy blue and cyan
 33 according to vaccine type and age, referring to <5 years CoronaVac, 5-11 years 0.1ml
 34 BNT162b2 and 11-18 years 0.3ml BNT162b2 respectively. Data points of patients who received
 35 intradermal 0.3ml BNT162b2 as dose 3 were depicted as rhombi, and those of infected patients
 36 were drawn to be hollow beginning from after the infection.




37

38 **FIG. 4. Correlation of surrogate virus neutralization test (sVNT) % levels with vaccine**
 39 **type (or age) and treatment.** sVNT results at 1 month after 2 doses were compared by
 40 unpaired t test after natural logarithmic transformation. KRT, kidney replacement therapy; IS,
 41 immunosuppressives



42

43 **FIG. 5. Adverse reactions (ARs) and antipyretic use reported 7 days after each dose by**
 44 **vaccine type.** Stacked bar chart shows ARs by maximal severity in different colors. C -
 45 CoronaVac, 0.1ml or 0.3ml B - BNT162b2.




46

47 **TABLE S1. Participant profile by treatment.** eGFR (estimated glomerular filtration rate) is
 48 estimated by modified Schwartz equation for participants below age 18 years and CKD-EPI
 49 formula for those above. KRT, kidney replacement therapy; NA - not applicable


Treatment	No KRT			On KRT	
	No IS	Any IS	Rituximab	Dialysis	Transplant
Participants <i>N</i>	5	31	9	13	15
Age mean (interquartile range)	6.5 (7.1-11.9)	11.9 (9.6-15.9)	13.4 (9.6-15.9)	14.3 (9.4-16.2)	12.9 (10.4-16.0)
Sex male n:female n	4:1	15:16	3:6	4:9	9:6
Vaccine and age					
CoronaVac, <5 years <i>n</i> (%)	2 (40%)	2 (6%)	1 (11%)	1 (8%)	0 (0%)
BNT162b2, 5-11 years, 0.1ml <i>n</i> (%)	2 (40%)	14 (45%)	2 (22%)	2 (15%)	7 (47%)
BNT162b2, 11-18 years, 0.3ml <i>n</i> (%)	1 (20%)	15 (48%)	6 (67%)	10 (77%)	8 (53%)
Completed 2 doses <i>n</i> (%)	5 (100%)	31 (100%)	9 (100%)	13 (100%)	15 (100%)
Completed 3 doses <i>n</i> (%)	4 (80%)	24 (77%)	5 (56%)	11 (85%)	12 (80%)
Type of kidney disease <i>n</i> (%)					
CAKUT	3 (60%)	0 (0%)	0 (0%)	1 (8%)	6 (40%)
Glomerular diseases	1 (20%)	30 (97%)	9 (100%)	3 (23%)	2 (13%)
Hereditary	0 (0%)	1 (3%)	0 (0%)	6 (46%)	4 (27%)
Miscellaneous	1 (20%)	0 (0%)	0 (0%)	3 (23%)	3 (20%)
Current immunosuppression within 3 months <i>n</i> (%)					
Mycophenolate mofetil	0 (0%)	21 (68%)	7 (78%)	1 (8%)	10 (67%)
Prednisolone	0 (0%)	19 (61%)	4 (45%)	4 (31%)	15 (100%)
Azathioprine	0 (0%)	1 (3%)	0 (0%)	0 (0%)	2 (13%)
Cyclosporine A	0 (0%)	1 (3%)	0 (0%)	0 (0%)	1 (7%)
Tacrolimus	0 (0%)	14 (45%)	6 (67%)	1 (8%)	14 (93%)
Everolimus	0 (0%)	0 (0%)	0 (0%)	0 (0%)	4 (27%)
Hydroxychloroquine	0 (0%)	5 (16%)	1 (11%)	1 (8%)	0 (0%)
Rituximab	0 (0%)	3 (10%)	3 (33%)	0 (0%)	0 (0%)
None	5 (100%)	0 (0%)	0 (0%)	9 (69%)	0 (0%)
Immunosuppression within 1 year <i>n</i> (%)					
Rituximab	0 (0%)	9 (29%)	9 (100%)	0 (0%)	0 (0%)
Kidney function mean (range)					
eGFR (ml/min/1.73m ²)	38.2 (20-88)	109.7 (25-234)	104.4 (25-234)	NA	62.8 (24-103)
Urine protein/ creatinine ratio (mg/mmol)	33.2 (1.6-91)	37.2 (6-140)	33.3 (6-108)	NA	26.4 (7-74)
Kidney failure vintage (year)	0 (0)	0 (0)	0 (0)	3.6 (1-14)	7.4 (3-18)
Blood count and comorbidities					
Hypertension <i>n</i> (%)	4 (80%)	15 (48%)	4 (44%)	11 (85%)	8 (53%)
Absolute lymphocyte count (x10 ⁹ /ml) mean (range)	3.9 (1.58-6.47)	2.5 (0.48-5.22)	2.4 (1.08-4.49)	2.1 (0.89-5.18)	2.5 (0.61-5.59)

50 **FIG. S1. IL-2⁺ T cell responses against wild-type SARS-CoV-2 proteins.** T cell responses
 51 against S protein were tested for all participants while responses against S, N and M proteins
 52 were only tested for CoronaVac. Geometric means (GM) are shown with center lines and stated
 53 above each column. Limits of detection and quantification (LOD and LOQ) and cut-offs were
 54 drawn as grey lines. Data points of patients who received intradermal 0.3ml BNT162b2 as dose
 55 3 were depicted as rhombi, and those of infected patients were drawn to be hollow beginning
 56 from after the infection. Data from the same participant were analyzed longitudinally by paired t
 57 test after natural logarithmic transformation, and the P values are denoted by asterisks (*,
 58 P<0.05; **, P<0.01; ns, not significant).



59

60 **FIG. S2. Hybrid sVNT and IFN- γ ⁺ T cell responses in patients infected prior to**
 61 **vaccination.** Geometric means (GM) are shown with center lines and stated above each
 62 column. Geometric means (GM) are shown with center lines and stated above each column.
 63 Limits of detection and quantification (LOD and LOQ) and cut-offs were drawn as grey lines.
 64 Data from the same participant were analyzed longitudinally by paired t test after natural
 65 logarithmic transformation, and the P values are denoted by asterisks (*, P<0.05; **, P<0.01; ns,
 66 not significant).



67